The burgeoning research on the short- and long-term adverse sequelae of perinatal depression on maternal, infant, and family health has prompted major medical and public health agencies to urge identification and treatment. Deaths due to psychiatric illness and drug overdose lead the causes of maternal mortality in the first year after birth.1 Finding novel treatments with improved effectiveness for depression in postpartum women is a pressing public health goal.
Wisner KL, Stika CS, Ciolino JD. The First Food and Drug Administration–Indicated Drug for Postpartum Depression—Brexanolone. JAMA Psychiatry. 2019;76(10):1001–1002. doi:10.1001/jamapsychiatry.2019.1546
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: